Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 1
Submit an article Journal homepage
112
Views
11
CrossRef citations to date
0
Altmetric
Review

Chemotherapy of malignant pleural mesothelioma

Pietro Bertino University of Hawaii, Cancer Research Center of Hawaii and Department of Pathology, 651 Ilalo Street, BSB Room 231, HI 96813, Honolulu, USA +1 808 440 4596; +1 808 587 0790; [email protected]; University of Piemonte Orientale “A Avogadro”, DISCAFF Department and DFB Center, Novara, Italy
,
Michele Carbone University of Hawaii, Cancer Research Center of Hawaii and Department of Pathology, 651 Ilalo Street, BSB Room 231, HI 96813, Honolulu, USA +1 808 440 4596; +1 808 587 0790; [email protected]
, MD PhD &
Harvey Pass New York University School of Medicine, Department of Cardiothoracic Surgery, NY 10016, New York, USA
Pages 99-107 | Published online: 16 Dec 2008

Bibliography

  • Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103(38):14128-33
  • Carbone M, Pass HI. Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol 2006;1(2):169-71
  • Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92(3):587-93
  • Nurminen M, Karjalainen A, Takahashi K. Estimating the induction period of pleural mesothelioma from aggregate data on asbestos consumption. J Occup Environ Med 2003;45(10):1107-15
  • Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345(8949)535-9
  • Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9(3)206-17
  • Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol 2004;159(2):107-12
  • Attanoos RL, Gibbs AR. The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology 2004;45(4):393-7
  • Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008;14(4):303-9
  • Nowak AK, Byrne MJ, Millward MJ, et al. Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opin Pharmacother 2004;5(12):2441-9
  • Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Williston Park) 2002;16(7):907-13; discussion 16-7, 19-20, 25
  • Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85(1):265-72; discussion 72
  • Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353(15):1564-73
  • Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10(1 Pt 1):184-90
  • Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993;105(4):743-7; discussion 7-8
  • Aelony Y, Yao JF, King RR. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. Respiration 2006;73(3):334-9
  • Chin YS, Yeghaian-Alvandi R, Noel M. Radiotherapy for the palliation of high-volume pleural effusion in malignant mesothelioma: case report. Palliat Med 2002;16(1):63-4
  • Bohle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion: Thoracoscopic talcum pleurodesis and pleuro-peritoneal shunt. Dtsch Med Wochenschr 1999;124(12):341-5
  • Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1(6):591-601
  • Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3(7):764-71
  • Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38(2):111-21
  • Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5(3):136-47
  • Bueno R, Appasani K, Mercer H, et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121(2):225-33
  • Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44
  • van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23(28):6881-9
  • Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6(4):363-73
  • Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21(8):1556-61
  • Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19(2):370-3
  • Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a Phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60(2):259-63
  • Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric Phase II study. Cancer 2003;97(11):2791-97
  • Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a Phase II trial. J Clin Oncol 2008;26(21):3567-72
  • Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18(23):3912-7
  • Fennell DA, C Steele JP, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005;47(2):277-81
  • O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17(2):270-5
  • Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26(10):1698-704
  • Sorensen JB, Sundstrom S, Perell K, Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007;2(2):147-52
  • Chen Y, Pandya K, Keng PC, et al. Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 2003;9(3):969-75
  • Rusch V, Saltz L, Venkatraman E, et al. A Phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994;12(6):1156-63
  • Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22(17):3451-7
  • Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117(1):54-63; discussion -5
  • Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18(7):1196-202
  • Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J Thorac Oncol 2006;1(4):289-95
  • Ambrosini V, Rubello D, Nanni C, et al. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur 2005;8(2):111-5
  • Alvarez JM, Ha T, Musk W, et al. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2005;130(3):905-6
  • Hoang CD, Zhang X, Scott PD, et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004;64(20):7479-85
  • Cacciotti P, Libener R, Betta P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001;98(21):12032-7
  • Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26(2):189-93
  • Kothmaier H, Quehenberger F, Halbwedl I, et al. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 2008;63(4):345-51
  • Catalano A, Rodilossi S, Rippo MR, et al. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004;279(45):46706-14
  • Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007;62(8):690-5
  • Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a Phase II trial. Lung Cancer 2005;50(1):83-6
  • Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59(1):149-50
  • Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004;31(2 Suppl 6):18-23
  • Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008;14(2):541-8
  • Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81(1):54-61
  • Karrison T. Final analysis of a multi-centre, double blind, placebo controlled, randomized Phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):7526
  • Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113(4):808-14
  • Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25(17):2406-13
  • Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;6510:4389-400
  • von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A Systematic Review of Phase II Trials of Thalidomide/Dexamethasone Combination Therapy in Patients with Relapsed or Refractory Multiple Myeloma. Eur J Haematol 2008;81(4):247-52
  • Biswas G, Narayanan P, Bhagwat R, et al. Thalidomide in primary peritoneal mesothelioma. J Surg Oncol 2006;93(5):434
  • Richly H, Henning BF, Kupsch P, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17(5):866-73
  • Buckstein R, Meyer RM, Seymour L, et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol 2007;14(4):154-61

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.